Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis

Eur J Clin Pharmacol. 2016 Feb;72(2):247-8. doi: 10.1007/s00228-015-1956-2. Epub 2015 Sep 24.
No abstract available

Keywords: Adverse events; Deferasirox; Hyperammonemia; Hyperchloremic metabolic acidosis.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters / genetics
  • Benzoates / adverse effects*
  • Benzoates / blood
  • Benzoates / therapeutic use
  • Child, Preschool
  • Deferasirox
  • Female
  • Glucuronosyltransferase / genetics*
  • Humans
  • Iron Chelating Agents / adverse effects*
  • Iron Chelating Agents / therapeutic use
  • Multidrug Resistance-Associated Protein 2
  • Multidrug Resistance-Associated Proteins / genetics*
  • Neoplasm Proteins / genetics
  • Polymorphism, Single Nucleotide
  • Thalassemia / blood
  • Thalassemia / drug therapy
  • Thalassemia / genetics*
  • Triazoles / adverse effects*
  • Triazoles / blood
  • Triazoles / therapeutic use

Substances

  • ABCG2 protein, human
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters
  • Benzoates
  • Iron Chelating Agents
  • Multidrug Resistance-Associated Protein 2
  • Multidrug Resistance-Associated Proteins
  • Neoplasm Proteins
  • Triazoles
  • UGT1A1 enzyme
  • Glucuronosyltransferase
  • Deferasirox